Multidisciplinary Care for Prostate Cancer ‘Should Always Happen’

The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.

Scott T. Tagawa, MD, MS, FACP, highlighted that a limited number of urologists had radioactive licenses, thus necessitating collaboration with radiation oncologists in procedures including administration of prostate-specific membrane antigen (PSMA)-PET scans to patients with prostate cancer.

Tagawa, a professor of medicine and urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine, spoke with CancerNetwork® about the importance of multidisciplinary care when it comes to administering radioactive therapy, at the 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.


We need to practice multidisciplinary care. My bias is that it should always happen for every kind of disease stage and state, from stage I through stage IV. Clearly, with the kind of onslaught [that] I hope is coming with these radiopharmaceuticals, we know that the vast majority of patients with advanced cancer are in the hands of medical oncologists or, in the case of prostate cancer, urologists. Essentially, a small handful have radioactive licenses. So, we have to work hand-in-hand with either radiation oncology, nuclear medicine, or both. And especially for the theranostics, there’s a diagnostic component in terms of patient selection. And even though that PSMA-PET is a little bit easier to read than some of the other PET agents like fluciclovine, there’s still pitfalls that are there. We have to work closely with them.

In terms of administration of these compounds, it’s got to be with someone that has a license. So again, radiation oncology, nuclear medicine, or both. And then we still need to see the patients, because we’re the ones that have been handling the patients the longest, and are most equipped to handle the other parts of their disease, as well as ongoing [androgen deprivation therapy], for instance, or bone health that needs to keep going. The other aspect of these that’s different than most of our other drugs is the potential for exposure to others: household members, the general public, our staff. That’s something that’s a little bit different; all of our radionuclides have half-lives, so this is most important in the first couple of days following administration. That’s something that’s a little bit different than we have with other drugs, so it’s something that we just need to be mindful of.

Related Videos
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
Related Content